MacroGenics Missed Consensus Estimates
Tuesday, May 13, 2025 at 4:01 PM ET
MacroGenics (MGNX) reported a loss of $0.65 per share on revenue of $13.19 million for the first quarter ended March 2025. The consensus estimate was a loss of $0.61 per share on revenue of $13.95 million. The company missed consensus estimates by 6.56% while revenue grew 44.90% on a year-over-year basis.
MacroGenics is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer.
Earnings Whisper Grade
Power Rating
-
-
Reported Earnings
$-0.65
Earnings Whisper®
-
Consensus Estimate
$-0.61
Earnings Surprise
Earnings Growth
Reported Revenue
$13.19 Mil
Revenue Estimate
$13.95 Mil
Revenue Surprise
Revenue Growth